Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;26(8):533–541. [Article in Spanish] doi: 10.1016/S0212-6567(00)78718-X

La hipertensión en los ancianos y resultados globales en salud con distintas terapias farmacológicas

Hypertension in the elderly and end-points in health with different pharmacological therapy

V Ruiz-García a,*, R Peiró b
PMCID: PMC7679585  PMID: 11149186

Abstract

Objectives

To describe the benefits of treatment for hypertension in the elderly, the most efficient drugs, those most widely used in clinical practice to reduce morbi-mortality taken from the literature.

Design

Systematic review.

Participants

Review study in Medline and the Cochrane Collaboration database. The antihypertensive pharmacological treatment is described (diuretics high and low dosage, calcium channel blockers, ACE inhibitor, and beta-blockers) administered to elderly people and their outcomes in morbi-mortality.

Measurements and main results

Reduction in coronary and cerebral morbidity and general, cardiovascular and cerebrovascular mortality.

Results

There is evidence to suggest that treatment for hypertension is helpful in the elderly, although efficiency is doubtful in patients over 80 years old. For persons aged over 65 general mortality is RR = 0.84 (0.75–0.94) and coronary morbidity RR = 0.80 (0.70–0.92). For persons aged over 80 general mortality is RR = 1 (0.86–1.17) and cardiovascular mortality is RR = 0.94 (0.75–1.18). Not all pharmacological groups produce the same results in mortality and morbidity. Diuretics (low dosage) offer better results than the remaining treatments reducing cardiovascular mortality as well cerebrovascular morbidity.

Conclusions

Treatment with drugs in hypertense elderly people is beneficial in terms of mortality and morbidity. Treatment with low dose diuretics, with or without potassium savers, is the elective treatment for hypertension in elderly patients.

Bibliografía

  • 1.Joint National Committee on detection, evaluation and treatment, of High Blood Pressure The sixth report of the Joint National Committee on detection, evaluation and treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413–2446. doi: 10.1001/archinte.157.21.2413. [DOI] [PubMed] [Google Scholar]
  • 2.The guideline subcommitte of the WHO/ISH mild hypertension liaison commitee 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization /international Society of Hypertension meeting. Hypertension. 1993;22:392–403. [PubMed] [Google Scholar]
  • 3.Sociedad-Liga Española para la Lucha contra la Hipertensión Arterial . IDEPSA; Madrid:: 1996. Control de la hipertensión en España. Ministerio de Sanidad y Consumo. [Google Scholar]
  • 4.Pardell H., Tresserras R., Armario P., Hernández R. Actions implemented to improve hypertension control in Spain. Am J Hypertens. 1998;11:763–765. doi: 10.1016/s0895-7061(98)00072-7. [DOI] [PubMed] [Google Scholar]
  • 5.Banegas J.R., Rodríguez-Artalejo F., Troca J.C., Castillon P.G., ReyCalero J. Blood pressure in Spain. Distribution, awareness, control and benefits of a reduction in average pressure. Hypertension. 1998;32:998–1002. doi: 10.1161/01.hyp.32.6.998. [DOI] [PubMed] [Google Scholar]
  • 6.ECEHA . Edipharma; Barcelona:: 1996. Estudio cooperativo sobre la hipertensión en el anciano. Fase I: prevalecia. [Google Scholar]
  • 7.Alli C., Avanzini F., Bettelli G., Colombo, Torri V., Tognoni G. The long term prognostic significance of repeated blood pressure measurements in the elderly SPAA (Studio sulla pressone arteriosa nell anciano) 10 year follow up. Arch Intern Med. 1999;159:1205–1212. doi: 10.1001/archinte.159.11.1205. [DOI] [PubMed] [Google Scholar]
  • 8.Coca A. Control de la hipertensión arterial en España. Resultados del estudio Controlpres 95. Hipertensión. 1995;12:182–188. [Google Scholar]
  • 9.Luque M. Fundación Ciencia y Medicina; Madrid:: 1995. Factores de riesgo cardiovascular. [Google Scholar]
  • 10.Jadad A. Randomised controlled trials A user's guide. In: Jadad A., editor. Assessing the quality of RCTs: why, what, how, and by whom? BMJ Books; Londres:: 1998. p. 138. [Google Scholar]
  • 11.Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R. Health outcomes associated with antihypertensive therapies used as first line agents. A systematic review and meta-analysis. JAMA. 1997;277:739–745. [PubMed] [Google Scholar]
  • 12.Guyatt G.H., Sackett D.L., Cook D.J. JAMA; Madrid:: 1997. por el Evidence-Based Medicine Working Group. Guías para usuarios de literatura médica: cómo utilizar un artículo de tratamiento o prevención. ¿Cuáles son los resultados? ¿Me ayudarán en la asitencia a mis pacientes? La medicina basada en la evidencia (guías del ususario de la literatura médica) pp. 35–44. [Google Scholar]
  • 13.Coope J., Warrender T. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145–1148. doi: 10.1136/bmj.293.6555.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Davis B.R., Vogt T., Frost P.H., Burlando A., Cohen J., Wilson A. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic hypertension in the Elderly Program Cooperative Research Group. Stroke. 1998;29:1333–1340. doi: 10.1161/01.str.29.7.1333. [DOI] [PubMed] [Google Scholar]
  • 15.Dahlöf B., Hansson L., Lindholm L., Schersten B., Wester P.O. STOP-hypertension-preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension. J Hypertens. 1987;5(Supl):607–610. [PubMed] [Google Scholar]
  • 16.Amery A., Brixko P., Clement D., De Shaepdryver A., Fagard R., Forte J. Mortality and morbidity results from the european working party on high blood pressure in the elderly trial. Lancet. 1985;1:1349–1354. doi: 10.1016/s0140-6736(85)91783-0. [DOI] [PubMed] [Google Scholar]
  • 17.Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrrier R.W. The effect on nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non insulin dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652. doi: 10.1056/NEJM199803053381003. [DOI] [PubMed] [Google Scholar]
  • 18.Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616. doi: 10.1016/s0140-6736(98)05012-0. [DOI] [PubMed] [Google Scholar]
  • 19.Hansson L., Lindholm L.H., Ekbom T., Dahlöf B., Lanke J., Scherstén B. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–1756. doi: 10.1016/s0140-6736(99)10327-1. [DOI] [PubMed] [Google Scholar]
  • 20.Hypertension-Stroke Cooperative Study Group Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409–418. doi: 10.1001/jama.1974.03230420021019. [DOI] [PubMed] [Google Scholar]
  • 21.MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–412. doi: 10.1136/bmj.304.6824.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Petrovitch H., Vogt T.M., Berge K.G. Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group. Geriatrics. 1992;47:30–32. [PubMed] [Google Scholar]
  • 23.Curb J.D., Pressel S.L., Cutler J.A. for the systolic in the Hipertension Eldelry Coperative Research Group. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886–1892. [PubMed] [Google Scholar]
  • 24.Sutton-Tyrrell K., Alcorn H.G., Herzog H., Kelsey S.F., Kuller L.H. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke. 1995;26:1319–1324. doi: 10.1161/01.str.26.8.1319. [DOI] [PubMed] [Google Scholar]
  • 25.Staessen J.A., Fagard R., Thijs L., Celis H., Birkenhager W.H., Bulpitt C.J. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med. 1998;158:1681–1691. doi: 10.1001/archinte.158.15.1681. [DOI] [PubMed] [Google Scholar]
  • 26.Dahlöf B., Lindholm L.H., Hansson L., Scherstén B., Ekbom T., Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991;338:1281–1285. doi: 10.1016/0140-6736(91)92589-t. [DOI] [PubMed] [Google Scholar]
  • 27.Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G., Birkenhäger W.H. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–764. doi: 10.1016/s0140-6736(97)05381-6. [DOI] [PubMed] [Google Scholar]
  • 28.Tuomilehto J., Rastenyte D., Birkenhager W.H., Thijs L., Antikainen R., Bulpitt C.J. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340:677–684. doi: 10.1056/NEJM199903043400902. [DOI] [PubMed] [Google Scholar]
  • 29.Mulrow C., Lau J., Cornell J., Brand M. Pharmacotherapy for hypertension in the elderly (Cochrane Review) The Cochrane Library. 1999;2:1–25. doi: 10.1002/14651858.CD000028. [DOI] [PubMed] [Google Scholar]
  • 30.Sanderson S. Hypertension in the elderly: pressure to treat? Health Trends. 1996;28:117–121. [Google Scholar]
  • 31.Lievre MLA Treatment of high blood pressure in patients aged over 60 years: lessons from randomized clinical trials. Cardiology in the Elderly. 1995;3:217–222. [Google Scholar]
  • 32.Gueyffier F., Bulpitt C., Boissel J.P., Schron E., Ekbom T., Fagard R. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999;353:793–796. doi: 10.1016/s0140-6736(98)08127-6. [DOI] [PubMed] [Google Scholar]
  • 33.Gueyffier F., Boutitie F., Boissel J.P., Pocok S., Coope J., Cutler J. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patiente data from randomized, controlled trials. The INDANA investigators. Ann Intern Med. 1997;126:761–767. doi: 10.7326/0003-4819-126-10-199705150-00002. [DOI] [PubMed] [Google Scholar]
  • 34.Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903–1907. doi: 10.1001/jama.279.23.1903. [DOI] [PubMed] [Google Scholar]
  • 35.Comite de Expertos de la OMS en Control de la Hipertensión . OMS; Ginebra:: 1994. Control de la hipertensión. [Google Scholar]
  • 36.Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95–110. doi: 10.1093/ajh/5.2.95. [DOI] [PubMed] [Google Scholar]
  • 37.Schmieder R.E., Martus P., Klingbeil A. A reversal of left ventricular hypertrophy in esential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507–1513. [PubMed] [Google Scholar]
  • 38.Levy D. Left ventricular hypertrophy: epidemiological insights from the Framingham Heart Study. Drug. 1988;35(Supl 5):1–5. doi: 10.2165/00003495-198800355-00002. [DOI] [PubMed] [Google Scholar]
  • 39.Pfeffer M.A., Braunwald E., Moyé L.A. for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left verntricular disfunction after myocardial infarction. N Engl J Med. 1992;327:669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  • 40.Levy D., Garrison R.J., Sagae D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass. N Engl J Med. 1990;322:1561–1566. doi: 10.1056/NEJM199005313222203. [DOI] [PubMed] [Google Scholar]
  • 41.Lewis E.J., Hunsicker L.G., Bain R.P., Rhode R.D. for the Collaborative Study Group. The effect of angiotensin-converting-enzime inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  • 42.Brown M.J., Palmer C.R., Castaigne A., De Leeuw P.W., Mancia G., Rosenthal T. Morbidity and mortality in patients randomised to double blind treatment with a long acting calcium channel blocker or diuretic in the Internatinal Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT) Lancet. 2000;356:366–372. doi: 10.1016/S0140-6736(00)02527-7. [DOI] [PubMed] [Google Scholar]
  • 43.Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet. 2000;356:359–365. doi: 10.1016/s0140-6736(00)02526-5. [DOI] [PubMed] [Google Scholar]
  • 44.García Ruiz A.J., García Ruiz I., Aranda Lara P., Montesinos A.C. Estudios sobre los enfermos hipertensos en tratamiento en España durante el período 1990–1993. Rev Esp Salud Pública. 1997;71:9–19. [PubMed] [Google Scholar]
  • 45.Neaton J.D., Grimm R.H., Prineas R.J., Stamler J., Grandits G.A., Elmer P.J. Treatment of mild hypertension study. JAMA. 1993;270:713–724. [PubMed] [Google Scholar]
  • 46.Kasiske B.L., Kalil R.S., Louis T.A. Antihipertensive agents affect serum lipid levels. Ann Intern Med. 1995;122:133–141. doi: 10.7326/0003-4819-122-2-199501150-00010. [DOI] [PubMed] [Google Scholar]
  • 47.Bronson D.L., Halperin A.K. Antihypertensive agents affect serum lipid levels. ACP Journal Club. 1995;123:151. [Google Scholar]
  • 48.Maugh T.H. A new wave of antibiotic builds. Science. 1981;214:1225–1228. doi: 10.1126/science.7302591. [DOI] [PubMed] [Google Scholar]
  • 49.Silverman M., Lee P.R. University of California Press; Berkeley:: 1974. Pills, profits, and politics; pp. 54–57. [Google Scholar]
  • 50.Anónimo Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud durante 1999. Inf Ter Sist Nac Salud. 2000;24:73–76. [Google Scholar]
  • 51.Reverte C.D., Moreno J.J., Ferreira E.M. Hipertensión arterial: actualización de su tratamiento. Inf Ter Sist Nac Salud. 1998;22:81–94. [Google Scholar]
  • 52.Pearce K.A., Furberg C.D., Psaty B.M., Kirk J. Cost minimization and the number to treat uncomplicated hypertension. Am J Hypertens. 1998;11:618–629. doi: 10.1016/s0895-7061(97)00488-3. [DOI] [PubMed] [Google Scholar]
  • 53.Weir M.R., Flack J.M., Applegate W.B. Tolerability, safety and quality of life and hypertensive therapy: the case for low dose diuretics. Am J Med. 1996;101(Supl 3A):83–92. doi: 10.1016/s0002-9343(96)00271-9. [DOI] [PubMed] [Google Scholar]
  • 54.Baos V. La calidad en la prescripción de medicamnetos. Inf Ter Sist Nac Salud. 1999;23:45–54. [Google Scholar]
  • 54.Staessen J.A., Thijs L., Gasowski J., Cells H., Fagard R.H. Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Am J Cardiol. 1998;82(9B):20–22. doi: 10.1016/s0002-9149(98)00752-8. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES